ENDRA Life Sciences to merge with Noble Africa (ASP Isotopes sub); raise $50M

ENDRA Life Sciences Inc.

Proposed merger of ENDRA subsidiary with Noble Africa LLC; combined entity Noble Africa Inc. to trade as NOBA.
Concurrent private placement to raise ~$50M gross; ASP Isotopes commits ~$20M, other investors ~$30M.
ASP Isotopes expected to own ~89% of combined company; ENDRA stockholders ~3%; other PIPE investors ~7%.
Transaction approved by both boards; expected close Q3/Q4 2026, subject to SEC registration and ENDRA stockholder approval.
Combined company led by Paul Mann (CEO of Renergen/ASP Isotopes) and Nick Mitchell; board with 5 ASPI designees, 1 ENDRA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.